Oct 30, 8:02 AM ET
On October 28, 2026, Azenta entered a license agreement and a supply agreement with Elegen Corp. for cell-free DNA synthesis technology, and acquired all outstanding stock of SynPlexity Inc., a DNA assembly technology company. The company expects aggregate capital deployment under the Elegen agreements of approximately $32 million to $71 million, depending on future equipment purchases and whether it converts the license to a perpetual one. The filing gives no revenue, profit, or guidance figures, so its direct effect on results is not quantified.
- Elegen license is exclusive and royalty-free for specified gene synthesis products, with an initial term of five years.
- Azenta has an option, exercisable 12 to 18 months after execution, to convert the license to a perpetual exclusive one for $25 million plus any unpaid license fees.
- Expected aggregate capital deployment under the Elegen agreements is approximately $32 million to $71 million.
- SynPlexity acquisition closed concurrently with signing on October 28, 2026; the filing does not state the purchase price.
Read the filing on SEC.gov ↗
Oct 7, 8:01 AM ET
Azenta said its board approved a restructuring plan on October 5, 2026, to consolidate its North American laboratory network, cut workforce and close three Multiomics sites in North America. The company estimates $11.0 million to $13.0 million in pre-tax charges, mostly non-cash impairments, with about $7.0 million in future cash spending and about $11.0 million in annualized savings once fully implemented.
- Plan approved October 5, 2026, within the Multiomics segment; employee notifications began October 6, 2026
- Estimated pre-tax charges of $11.0 million to $13.0 million, including about $9.0 million of asset impairment and about $3.0 million of severance and other restructuring
- Estimated future cash expenditures of about $7.0 million; expected annualized cost savings of about $11.0 million
- Most charges expected in the fiscal year ending September 30, 2027; actions substantially complete by March 31, 2027
Read the filing on SEC.gov ↗
Sep 17, 3:48 PM ET
Azenta's board approved a letter agreement with Dr. Martin D. Madaus, its Interim President and Chief Executive Officer since August 22, 2026, setting his base salary, a cash performance bonus, and an equity grant. The company also granted retention restricted stock units to four named executive officers, including $1,000,000 for Chief Financial Officer Lawrence Lin. The filing discloses pay terms and governance changes, and it does not report financial results.
- Madaus receives an annual base salary of $600,000 and a cash performance recognition bonus equal to 100% of salary, which vests on the first anniversary of his start date.
- Madaus receives restricted stock units with an award value of $1,200,000, vesting in 1/12 monthly installments from his start date.
- Retention awards: Lawrence Lin $1,000,000; Ephraim Starr, Olga Pirogova and Trey Martin $500,000 each, with 50% vesting on each of the first and second anniversaries of the September 14, 2026 grant date.
- Madaus left the Nominating and Governance Committee, which now consists of William L. Cornog (Chair), Frank E. Casal and Robyn C. Davis.
Read the filing on SEC.gov ↗
Aug 24, 8:03 AM ET
Azenta's President and CEO John Marotta resigned from the company and its Board effective August 22, 2026, and the Board named director Dr. Martin Madaus as interim President and CEO. The company reaffirmed its fourth quarter fiscal 2026 total revenue guidance but expects a one-time approximately $3 million consulting expense to affect fourth quarter adjusted EBITDA, and a search for a permanent CEO is underway.
- John P. Marotta resigned as President, CEO and director effective August 22, 2026; the company says the resignation was not due to any disagreement on operations, policies or practices.
- Dr. Martin D. Madaus, a Board member since January 2024, was elected interim President and CEO effective August 22, 2026, and will step down from the Nominating and Governance Committee chair role.
- Fourth quarter fiscal 2026 total revenue guidance, issued August 4, 2026, was reaffirmed; adjusted EBITDA will be affected by a one-time approximately $3 million consulting expense.
- The Board reduced its size from nine to eight members, and the company has retained Heidrick & Struggles to search for a permanent CEO.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.